Andrew Cheng
About Andrew Cheng
Andrew Cheng President and CEO
Andrew Cheng serves as the President and Chief Executive Officer. With nearly two decades of experience at Gilead Sciences, where he last held the position of Chief Medical Officer, Cheng brings extensive leadership and expertise to the role. His strategic vision and in-depth knowledge of the pharmaceutical industry have been instrumental in driving company initiatives and leading the team toward achieving significant milestones.
Andrew Cheng Education
Andrew Cheng holds a B.A. in biology from Johns Hopkins University, one of the leading research universities. He further pursued his education at Columbia University College of Physicians and Surgeons, where he earned both an M.D. and Ph.D. in cellular and molecular biology. His academic background is rooted in rigorous medical and scientific training, providing a strong foundation for his career in the pharmaceutical and biotech industries.
Andrew Cheng Gilead Sciences
During his 19-year tenure at Gilead Sciences, Andrew Cheng held several leadership roles, culminating in his position as Chief Medical Officer. He was a driving force behind the clinical development of the HIV program, which resulted in 11 FDA/EMA approved products. Cheng's work has had a significant impact on the field of HIV treatment and showcases his commitment to advancing medical therapies.
Andrew Cheng Board Director Positions
Andrew Cheng serves on the board of directors for Vera Therapeutics and MorphoSys. His extensive experience in the pharmaceutical industry provides valuable insights and guidance to these organizations. Previously, he also served on the boards of Arbutus Biopharma and privately held Syntimmune, which was later acquired by Alexion. These roles highlight his expertise and leadership within the biotech sector.
Andrew Cheng Medical Training
Andrew Cheng completed his internal medicine residency at UCLA and was board certified in internal medicine. His medical training included extensive hands-on experience in patient care and clinical practice, equipping him with a practical understanding of internal medicine. This background has contributed to his comprehensive approach to clinical development and medical strategy.